超声引导下经皮经肝无水乙醇注射联合索拉非尼口服治疗原发性肝癌临床评价

目的 探讨超声引导下经皮经肝无水乙醇注射联合索拉非尼治疗原发性肝癌的临床效果及对术后复发情况的影响。方法 选取沧州市传染病医院2014年1月至2015年12月收治的原发性肝癌患者92例,按随机数字表法分为观察组和对照组,各46例。两组患者均予超声引导下经皮经肝无水乙醇注射治疗,观察组患者加服甲苯磺酸索拉非尼片。统计并比较两组患者的近期疗效、血清肿瘤标志物水平、不良反应发生率,并门诊随访3年以观察肿瘤复发率、远端转移率、死亡率。结果 观察组近期有效率为86.96%,明显高于对照组的69.57%(P<0.05);治疗后,观察组患者的甲胎蛋白(AFP)、癌胚抗原(CEA)、血管内皮生长因子(VEGF)水平均明显低于对照组(P<0.05);治疗期间,观察组不良反应发生率为21.74%,与对照组的13.04%相当(P>0.05)。门诊随访3年,观察组肿瘤复发率、远端转移率、死亡率均明显低于对照组(P<0.05)。结论 超声引导下经皮经肝无水乙醇注射联合索拉非尼口服治疗原发性肝癌,能提高近期疗效,降低患者体内血清肿瘤标志物水平和复发率。

Contrast-Enhanced Ultrasound-Guided Percutaneous Transhepatic Ethanol Injection Combined with Sorafenib in the Treatment of Hepatocellular Carcinoma

Objective To investigate the clinical efficacy of percutaneous transhepatic ethanol injection combined with sorafenib guided by contrast-enhanced ultrasound in the treatment of patients with hepatocellular carcinoma(HCC)and its effect on postoperative recurrence.Methods A total of 92 patients with hepatocellular carcinoma admitted to the hospital from January 2014 to December2015 were selected and divided into the observation group and control group according to random number table method,46 cases in each group.The control group was treated with percutaneous transhepatic ethanol injection under the guidance of contrast-enhanced ultrasound,and the observation group was added with sorafenib on this basis.The short-term curative effect,serum tumor markers and incidence of adverse reactions were compared between the two groups.The patients in the two groups were followed for 3 years,and the recurrence rate,distal metastasis rate and mortality rate of tumors in the two groups within 3 years were compared.Results The total effective rate in the observation group was 86.96%,which was significantly higher than 69.57%in the control group(P<0.05).After treatment,the serum levels of alpha-fetoprotein(AFP),carcino-embryonic antigen(CEA)and vascular endothelial growth factor(VEGF)in the observation group were significantly lower than those in the control group(P<0.05).The incidence of adverse reactions was 21.74%in the observation group and 13.04%in the control group;there was no significant difference between the two groups(P>0.05).After 3 years of follow-up,the recurrence rate,distal metastasis rate and mortality of the patients in the observation group were significantly lower than those in the control group(P<0.05).Conclusion Contrast-enhanced ultrasound-guided percutaneous ethanol injection combined with sorafenib in the treatment of hepatocellular carcinoma patients can improve the short-term efficacy of patients,reduce the level of serum malignant biological indicators in patients and the recurrence rate.